scholarly journals Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab

2016 ◽  
Vol 43 (5) ◽  
pp. 901-906 ◽  
Author(s):  
Jürgen Braun ◽  
Xenofon Baraliakos ◽  
Kay-Geert A. Hermann ◽  
Stephen Xu ◽  
Benjamin Hsu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Ankylosing Spondylitis ◽  
Growth Factor ◽  
Controlled Trial ◽  
Placebo Control ◽  
Vascular Endothelial ◽  
Double Blind ◽  
Link Type ◽  
Increased Risk ◽  
Endothelial Growth Factor

Objective.To assess vascular endothelial growth factor (VEGF) correlations with new bone formation and bone marrow edema in patients with ankylosing spondylitis (AS) treated with golimumab (GOL).Methods.Following placebo control (through weeks 16 and 24), GO-RAISE (A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis; ClinicalTrials.gov: NCT00265083) all patients received GOL; sera/images were available at weeks 0, 104, and 208. Lateral spinal radiographs and magnetic resonance imaging (MRI) were scored using the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and the Ankylosing Spondylitis Spinal MRI activity score, respectively.Results.VEGF levels and the mSASSS did not significantly correlate. Logistic regression analyses showed no association between VEGF levels and an increased risk of syndesmophyte formation at weeks 104 and 208. Pretreatment/Week 14 VEGF did not predict MRI scores/changes at Week 104.Conclusion.Serum VEGF did not predict radiographic progression/spinal inflammation in patients receiving antitumor necrosis factor.

Vascular Endothelial Growth Factor (VEGF) in Ankylosing Spondylitis - a Pilot Study

2002 ◽  
Vol 152 (9-10) ◽  
pp. 223-225 ◽  
Author(s):  
C. Goldberger ◽  
J. Dulak ◽  
C. Duftner ◽  
F. Weidinger ◽  
A. Falkenbach ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Ankylosing Spondylitis ◽  
Pilot Study ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Plasma Levels of Vascular Endothelial Growth Factor and Selected Hemostatic Parameters in Association With Treatment Response in Multiple Myeloma

2019 ◽  
Vol 25 ◽  
pp. 107602961882328
Author(s):  
Juraj Sokol ◽  
Matej Hrncar ◽  
Frantisek Nehaj ◽  
Jan Stasko
Keyword(s):  
Multiple Myeloma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Clinical Stage ◽  
Vascular Endothelial ◽  
Newly Diagnosed ◽  
Successful Therapy ◽  
Coagulation Activity ◽  
Increased Risk ◽  
Endothelial Growth Factor

Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the clonal proliferation of plasma cells in the bone marrow and presence of monoclonal protein in the blood or urine. Diverse hemostatic abnormalities have been reported in patients with myeloma which predispose the patient to bleeding and also thrombosis. The aim of this study was to measure the concentrations of serum levels of vascular endothelial growth factor, D-dimer, and von Willebrand factor in patients with newly diagnosed or relapsed multiple myeloma before treatment, during therapy, and after successful therapy. The working hypothesis was that all of these factors reflect the total body burden of tumor. Angiogenic and coagulation activity should therefore decrease after successful therapy. Our study indicates that selected prothrombotic abnormalities occur in patients with MM, which may contribute to the increased risk of venous thromboembolism observed in these patients. The levels of our 3 parameters were strongly elevated in patient with newly diagnosed MM and also in patients with clinical stage III based on International Staging System criteria. Furthermore, there was a correlation between prognostic disease stages in all study population. It would be appropriate to include angiogenic and coagulation parameters into prognostic parameters.

Vascular endothelial growth factor gene polymorphisms and risk of colorectal cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4123-4123
Author(s):  
Y. Cho ◽  
Y. Chae ◽  
J. Kim ◽  
S. Shon ◽  
J. Moon ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Angiogenic Factor ◽  
Control Group ◽  
Vascular Endothelial ◽  
Pathologic Features ◽  
Increased Risk ◽  
Endothelial Growth Factor ◽  
Vegf Polymorphisms

4123 Background: Angiogenesis is closely related to the development, growth, and metastasis of solid tumors, including colorectal cancer (CRC), and the vascular endothelial growth factor (VEGF) is known to be a potent pro-angiogenic factor. Accordingly, the present study was conducted to evaluate the potential association between two VEGF polymorphisms (+405G > C, and 936C > T) and the risk of CRC. Methods: The VEGF genotypes were determined using fresh colorectal tumor tissue from 477 patients with CRC who underwent surgical resection and peripheral blood lymphocytes from 413 healthy controls based on a polymerase chain reaction/denaturing high-performance liquid chromatography (PCR/DHPLC) assay. The incidence of genotypes and haplotypes of two VEGF polymorphisms was compared between the patients with CRC and the controls. Results: The distribution of genotypes and allele frequencies of the 936C > T polymorphism in the CRC group did not differ from those in the control group. However, compared with the combined GC and CC genotype, the GG genotype of +405G > C polymorphism was significantly associated with an increased risk of CRC [odds ratio (OR), 1.575; 95% confidence interval (CI), 1.178–2.104; P = 0.002]. In the haplotype analyses, haplotype +405G / 936C was also associated with a significantly increased risk of CRC (OR, 1.264; 95% CI, 1.043–1.531; P = 0.017), whereas haplotype +405C / 936C was associated with a decreased risk of CRC (OR, 0.818; 95% CI, 0.677–0.989; P = 0.038). None of the VEGF polymorphisms studied significantly influenced the clinical or pathologic features of CRC. Conclusions: These findings suggest that the VEGF +405G > C polymorphism may be associated with the risk of CRC in the Korean population. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document